






US 20110152967A1

(19) **United States**(12) **Patent Application Publication**  
**Simon et al.**(10) **Pub. No.: US 2011/0152967 A1**(43) **Pub. Date: Jun. 23, 2011**(54) **NON-INVASIVE TREATMENT OF  
NEURODEGENERATIVE DISEASES**(75) Inventors: **Bruce Simon**, Mountain Lakes, NJ  
(US); **Joseph P. Errico**, Warren, NJ  
(US); **John T. Raffle**, Austin, TX  
(US)(73) Assignee: **ElectroCore, LLC.**, Morris Plains,  
NJ (US)(21) Appl. No.: **13/005,005**(22) Filed: **Jan. 12, 2011****Related U.S. Application Data**(63) Continuation-in-part of application No. 12/964,050,  
filed on Dec. 9, 2010, which is a continuation-in-part  
of application No. 12/859,568, filed on Aug. 19, 2010,  
said application No. 12/859,568 is a continuation-in-  
part of application No. 12/408,131, filed on Mar. 20,  
2009.(60) Provisional application No. 61/415,469, filed on Nov.  
19, 2010.**Publication Classification**(51) **Int. Cl.**  
**A61N 1/36** (2006.01)(52) **U.S. Cl.** ..... **607/45**(57) **ABSTRACT**

Methods and devices are disclosed for the non-invasive treatment of neurodegenerative diseases through delivery of energy to target nervous tissue, particularly the vagus nerve. The devices include a magnetic stimulator having coils with toroidal windings, which are in contact with an electrically conducting medium that is adapted to conform to the contour of a target body surface of a patient. The coils induce an electric current and/or an electric field within the patient, thereby stimulating nerve fibers within the patient. The stimulation brings about reduction of neuroinflammation in patients suffering from conditions comprising Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, postoperative cognitive dysfunction and postoperative delirium. Reduction in inflammation is effected by enhancing the anti-inflammatory competence of cytokines such as TGF-beta, wherein a retinoid or components of the retinoic acid signaling system provide an anti-inflammatory bias, by enhancing anti-inflammatory activity of a neurotrophic factor such as NGF, GDNF, BDNF, or MANF, and/or by inhibiting the activity of pro-inflammatory cytokines such as TNF-alpha.











FIG. 5



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.